CN110151885A - A kind of niacinamide-containing mononucleotide formula is in the application for preparing anti-aging and nutritive health care product or medicine field - Google Patents
A kind of niacinamide-containing mononucleotide formula is in the application for preparing anti-aging and nutritive health care product or medicine field Download PDFInfo
- Publication number
- CN110151885A CN110151885A CN201910485152.8A CN201910485152A CN110151885A CN 110151885 A CN110151885 A CN 110151885A CN 201910485152 A CN201910485152 A CN 201910485152A CN 110151885 A CN110151885 A CN 110151885A
- Authority
- CN
- China
- Prior art keywords
- aging
- health care
- extract
- parts
- niacinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of niacinamide-containing mononucleotides, the composition of biotin and acai berry extract, and its in the application for preparing anti-aging and nutritive health care product or medicine field.It is described in the application for preparing anti-aging and nutritive health care product or medicine field, refer to and the anti-apolexis composition be made to the dosage form that granule, tablet, capsule, oral solution etc. are taken for the mankind together with other auxiliary materials.Three kinds of group of effective components are combined by the present invention, play synergistic function, by rational proportion, make it have anti-senescence function.It can reduce the symptom of the parkinsonism due to caused by aging, Alzheimer syndrome and cardiovascular and cerebrovascular disease simultaneously, and there is strengthen immunity, prevent and treat tumor function.
Description
Technical field
The present invention relates to medical health fields, more particularly to a kind of composition for infirmities of age treatment.
Background technique
With the development and social progress of medicine, the service life of the mankind is increasingly longer, now results in the master of the elderly's death
Factor such as cardiovascular disease etc. is wanted there are more effective treatment means, therefore the death rate of the elderly is greatly lowered, always
The result is that population ratio shared by the elderly is higher and higher.
The people at advanced age is more and more, but the quality of life of these people is not improved accordingly, caused by some agings
Disease still annoyings the elderly.It by taking Alzheimer's disease as an example, data show, the disease incidence of over-65s crowd is
4.8%, the disease incidence of 85 years old or more crowd increases to 8%.Therefore, the health status for improving the elderly improves the life of the elderly
Bioplasm amount is just at the major issue of current social extensive concern.
Aging is the progressive process of bio-tissue, organ and cell loss of function at any time and gradually.Diabetes are
Caused by declining as the functional deterioration of islet cells or human tissue cell to the sensibility of insulin, gout is because of kidney
Histocyte aging to function is lost, caused by leading to uric acid excretion disorder；Hypertension and heart, kidney, blood vessel are isocellular
Dysfunction has some relations；Alzheimer's disease and parkinsonism are then as caused by brain nervous cell functional deterioration.
Current technology means, treating degenerative disease caused by aging can only be treated to the ill, that is, in disease
Disease symptoms just start interventional therapy after occurring, though such method has certain effect, patient body function
It is subjected to degenerating or damage, quality of life is decreased obviously, and therapeutic effect when this is not so good.Importantly, the elderly
A variety of infirmitiess of age are often suffered from, while treating a variety of diseases of old people, there are biggish limitations for current technology.For diseases of aging
General character treated, be a completely new field to be had effect to a variety of diseases of aging.
Summary of the invention
The invention mainly solves the technical problem of providing a kind of composite formulas, can effectively intervene and delay to decline
Always, improve the holistic health of the elderly.
In order to solve the above technical problems, the technical solution adopted by the present invention is that: a kind of niacinamide-containing mononucleotide, life are provided
Object element, acai berry extract, synergist, promotor composition, which is characterized in that be grouped as by the group of following weight fraction:
100 ~ 200 parts of nicotinamide mononucleotide, 30 ~ 100 parts of acai berry extract, 50 ~ 100 parts of synergist, promotees 10 ~ 50 parts of biotin
Into 100 ~ 200 parts of agent；
The synergist is made of two kinds in grape extract, Gentrin Knotweed P.E, peanut extract, blueberry extract；
The promotor is made of two kinds in propylene glycol, polyethylene glycol, carbomer.
The composition can play therapeutic effect by oral.
The present invention compared with the existing technology, has the following advantages and effect:
(1) invention introduces synergist and promotor, and anti-aging effects are more preferable, can reduce the Parkinson due to caused by aging
Disease, Alzheimer syndrome and cardiovascular and cerebrovascular disease symptom, and with strengthen immunity, prevent and treat tumour function
Effect.
(2) composition of the invention can be played a role by oral, and easy to use, risk is extremely low.
(3) composition of the invention can be taken for a long time, be free from side effects and adverse reaction.
Detailed description of the invention
Fig. 1 is the SA- β-gal using the people WI-38 fibroblast (experimental group) after compositions-treated of the invention
Dyeing；
Fig. 2 is the SA- β-gal dyeing that the people WI-38 fibroblast (control group) of compositions-treated of the invention is not used；
Specific embodiment
The preferred embodiments of the present invention will be described in detail with reference to the accompanying drawing, so that advantages and features of the invention energy
It is easier to be readily appreciated by one skilled in the art, so as to make a clearer definition of the protection scope of the present invention.But this
The embodiment of invention is without being limited thereto.
The embodiment of the present invention one:
A kind of 1 composition and preparation method thereof with senile-resistant efficacy:
60g propylene glycol, 50g polyethylene glycol are dissolved in 1000g high purity water, 200g nicotinamide mononucleotide, 15g is then added
Biotin, 50g acai berry extract, 10g grape seed extract, 60g blueberry extract, stir evenly after making it completely dissolved,
It is sterilized with Co60- gamma-ray irradiation, dosage 9kGy is denoted as anti-aging solution, spare.
2 cell culture
Cellular control unit culture: by normal human's fibroblast WI-38 strain, with DMEM culture solution (10% fetal calf serum of addition
And 100X Pen .- Strep) secondary culture is to 30 generations, inoculation 2 × 104~5×104Cell after a secondary culture is trained in 35mm
It supports in ware, cultivates 3 days, with phosphate buffer solution (1.37mol/L NaCl, 27mmol/L KCl, 100 mmol/L
Na2HPO4, 18mmol/L KH2PO4) wash cell twice, it is solid with the 3.7% formaldehyde phosphate buffer solution now matched at room temperature
Determine cell 3 ~ 5 minutes, washed cell 2 times with phosphate buffer solution, X-gal dyeing liquor is added, and (culture dish of each 35mm adds
Enter 1 ~ 2mL), dyeing liquor incubated cell is used at 37 DEG C, and some cell indigo plants dyes can be observed in 2 hours, reach most after 12 ~ 16 hours
Big degree dyeing, as shown in Figure 2.
Experimental group cell culture: by normal human's fibroblast WI-38 strain, with DMEM culture solution (10% tire ox of addition
Serum, 100X Pen .- Strep, anti-aging solution) secondary culture is to 30 generations, inoculation 2 × 104~5×104After a secondary culture
Cell in 35mm culture dish, cultivate 3 days, with phosphate buffer solution (1.37mol/L NaCl, 27mmol/L KCl,
100 mmol/L Na2HPO4, 18mmol/L KH2PO4) wash cell twice, at room temperature with the 3.7% formaldehyde phosphate now matched
It buffer solution fixed cell 3 ~ 5 minutes, is washed cell 2 times with phosphate buffer solution, X-gal dyeing liquor (each 35mm is added
Culture dish 1 ~ 2mL is added), dyeing liquor incubated cell is used at 37 DEG C, some cell indigo plants dyes can be observed in 2 hours, 12 ~ 16 is small
When after reach and utmostly dye, as shown in Figure 1.
The analysis of 3 anti-aging solution efficacies
Beta galactosidase (SA- β-gal) be culture in or in vivo senile cell a kind of good biomarker.This mark
Will object is only expressed in senile cell, and without expressing before aging or in the fibroblast of resting stage, it is tight with senescent phenotypes
Close correlation, its expression frequency will increase in aging tissues, this with internal senile cell with age and what is accumulated show
As consistent.Therefore, the contents level for detecting intracellular SA- β-gal can reflect the aging degree of cell.Experimental group addition
Anti-aging solution, the dye levels for turning out the cell come are extremely shallow (as shown in Figure 1), show the level of beta galactosidase
It is low, therefore the present invention has anti-aging effects.
The embodiment of the present invention two:
1. a kind of composition and preparation method thereof with senile-resistant efficacy:
60kg propylene glycol, 50kg polyethylene glycol are heated to melting, 100g nicotinamide mononucleotide, 15kg are added after mixing
Biotin, 50kg acai berry extract, 10kg grape seed extract, 60kg blueberry extract are pressed into flexible glue after crossing homogenizer
Capsule, loading amount is 1g/, as anti-age capsule.
2. clinical test methods
A, it chooses general information and is diagnosed as 208 of gouty arthritis,chronic and be hospitalized or outpatient, be randomly divided into treatment group
And control group；Wherein, treatment group 104, male 84, female 20；41 years old and 41 years old or less 10,42~51 years old 46,52~
61 years old 36,61 years old or more 12；The course of disease is most 8 months short, and longest 23 years, average course of disease 4.0 years.Control group 104, male 80
Example, female 24；40 years old and 40 years old or less 10,41~50 years old 44,51~60 years old 36,60 years old or more 14；The course of disease is most short by 7
A month, longest 22 years, average course of disease 3.9 years；Two groups of genders, age, courses of disease are statistically analyzed, difference there are no significant meaning
(P > 0.05), is comparable.
B, diagnostic criteria referring to the Ministry of Public Health publication " new Chinese medicine guideline of clinical investigations " in Meng Zhao henry propose it is slow
The diagnostic criteria of property urarthritis.
Treatment method is as follows:
Treatment group: taking anti-age capsule as described in example 2,2 times a day, each 1 time sooner or later, and 1 tablet each time,；Control group: every
It is secondary to take Allopurinol 0.1g, 1 day 2~3 times, Mei Luopukang daily 1 time, each 7.5mg.Two groups of equal 15 days as a treatment course.
C, symptom and sign grade scale is as follows:
(1) pain degree: 0 point, joint without pain；1 point, there is pain in without pain when joint is inactive, when joint motion；It 2 points, closes
Save inactive Shi Yiyou pain, pain aggravates when joint motion；3 points, sharp ache, joint motion is obviously limited because of pain.
(2) swelling degree: 0 point, joint is without swelling；1 point, arthroncus, but juxtra-articular apophysis is had not exceeded at swelling
Portion out；2 points, arthroncus is more obvious, equal with bony prominence at swelling；3 points, joint height swelling, at swelling
Higher than bony prominence.
(3) 0 point, various activities can range of motion: be done；1 point, moderate is limited, and joint motion is not flexible, can be engaged in normal
Activity；2 points, hence it is evident that it is limited, it can only take care of oneself, but general activity cannot be engaged in；3 points, movable function is lost, and life cannot be certainly
Reason.
D, curative effect determinate standard of the criterion of therapeutical effect referring to the Zhao Zhaolin and Meng Zhaoheng related urarthritis proposed:
(1) clinical cure: blood uric acid restores normal, and joint distending pain subsides, and movable function restores normal, and tophus disappears, respectively
Item integral only has 0-1 points；
(2) effective: gout symptom disappears substantially, and blood uric acid declines on a large scale up to normal level or, and arthroncus does not restore
Normally but most of to subside, joint movement function still has an obstacle to a certain degree, and tophus is obviously reduced but not yet completely
Subside, integral decline >=2/3；
(3) effectively: between it is effective with it is invalid between, each symptom and sign makes moderate progress, integral between it is effective in vain between；
(4) invalid: various aspects are unchanged or aggravate instead, integral decline < 1/3.
Calculation formula (Nimodipine method) is [(pre-treatment score-post treatment integral)+pre-treatment score] × 100%.
E, treatment results are as follows:
Sings and symptoms integral contrast is shown in Table 1 after (1) two group of patient treats two courses for the treatment of.
1 two groups of patients of table treat sings and symptoms integral contrast after three courses for the treatment of (±s)
Note: * indicates P < 0.01 compared with before treatment after treatment；Comparing Δ Δ Δ after two treatments indicates P < 0.05.
(2) compare the influence that two groups for the treatment of methods improve blood uric acid, the blood uric acid value after two groups of patient's treatments is relatively controlled
Improve before treating, but the decline for the treatment of group's uric acid of patient becomes apparent from (P < 0.05) compared with control group and is shown in Table 2.
2 two groups of pretherapy and post-treatment blood uric acid value of table comparison (±s)
Note: Δ indicates that the P < 0.01 compared with before treatment, * indicate that P < 0.05 compared with the control group, # indicate P compared with the control group
< 0.05.
Statistics curative effect is shown in Table 3 after (3) two groups of patients treat three courses for the treatment of.
Curative effect compares after 3 two groups of patients of table treat three courses for the treatment of
Two groups of patient's curative effect comparing differences have significant (P < 0.01).
F, the adverse reaction situation of two groups of patients compares
Control group has 17, the bored discomfort that occurs that nauseous, gastral cavilty portion is swollen after medication 2-3 week, secret anguish, difference of receiving, have 13 after 3 weeks
There is pruitus, there are 25 hepatic disorder occur after 4 weeks；
Treatment group have 3 take traditional Chinese medicine after tell it is slightly nauseous, without receiving poor, gastral cavilty portion discomfort, no hepatic disorder.
According to the result of experimental example, it is clear that improvement gout composition proposed by the present invention has as alleviation or treatment
The value of gout drug development.
3, clinical efficacy is summarized
The present invention treats 132, and as a result clinical cure 30, account for 22.7%, effective 52, account for 39.4%, effective 41, account for
31.1%, no effect 9 accounts for 6.8%, total effective rate 93.2%.Illustrate that the present invention has effect to the functional rehabilitation of kidney cell.
The above description is only an embodiment of the present invention, is not intended to limit the scope of the invention, all to utilize this hair
Equivalent structure or equivalent flow shift made by bright specification and accompanying drawing content is applied directly or indirectly in other relevant skills
Art field, is included within the scope of the present invention.
Claims (4)
1. the composition of a kind of niacinamide-containing mononucleotide, biotin, acai berry extract, synergist, promotor, feature exist
In being grouped as by the group of following weight fraction: 100 ~ 200 parts of nicotinamide mononucleotide, 10 ~ 50 parts of biotin, the Brazilian certain kind of berries extract
30 ~ 100 parts of object, 50 ~ 100 parts of synergist, 100 ~ 200 parts of promotor.
2. composition according to claim 1, it is characterised in that: the synergist is mentioned by grape extract, polygonum cuspidate
Take object, peanut extract, two kinds of compositions in blueberry extract.
3. composition according to claim 1, it is characterised in that: the promotor is by propylene glycol, polyethylene glycol, card
Two kinds of compositions in wave nurse.
4. with composition described in claim 1 come the delaying human body caducity prepared or drug or the health care for the treatment of aging complication
Product, and it is played a role by oral.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910485152.8A CN110151885A (en) | 2019-06-05 | 2019-06-05 | A kind of niacinamide-containing mononucleotide formula is in the application for preparing anti-aging and nutritive health care product or medicine field |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910485152.8A CN110151885A (en) | 2019-06-05 | 2019-06-05 | A kind of niacinamide-containing mononucleotide formula is in the application for preparing anti-aging and nutritive health care product or medicine field |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110151885A true CN110151885A (en) | 2019-08-23 |
Family
ID=67627700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910485152.8A Withdrawn CN110151885A (en) | 2019-06-05 | 2019-06-05 | A kind of niacinamide-containing mononucleotide formula is in the application for preparing anti-aging and nutritive health care product or medicine field |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110151885A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112535289A (en) * | 2020-12-17 | 2021-03-23 | 四川即醉科技有限公司 | NMN-containing composition capable of delaying senescence and preparation method and application thereof |
| WO2022042615A1 (en) * | 2020-08-25 | 2022-03-03 | 大江生医股份有限公司 | Yeast powder rich in nicotinamide mononucleotide, preparation method therefor, and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
| CN109350557A (en) * | 2018-05-25 | 2019-02-19 | 泓博元生命科技（深圳）有限公司 | Anti-apolexis composition, skin care item comprising NADH and ceramide and the preparation method and application thereof |
-
2019
- 2019-06-05 CN CN201910485152.8A patent/CN110151885A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104814974A (en) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | Application of nicotinamide mononucleotide in preparation of anti-aging drugs or health care products |
| CN109350557A (en) * | 2018-05-25 | 2019-02-19 | 泓博元生命科技（深圳）有限公司 | Anti-apolexis composition, skin care item comprising NADH and ceramide and the preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 佚名: "日美开展抗衰老物质人体临床试验", 《广州医科大学学报》 * |
| 佚名: "美国科学家发现天然化合物烟酰胺单核苷酸能抗衰老", 《生物学教学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022042615A1 (en) * | 2020-08-25 | 2022-03-03 | 大江生医股份有限公司 | Yeast powder rich in nicotinamide mononucleotide, preparation method therefor, and application thereof |
| CN112535289A (en) * | 2020-12-17 | 2021-03-23 | 四川即醉科技有限公司 | NMN-containing composition capable of delaying senescence and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhasker et al. | Molecular evidence of insulinomimetic property exhibited by steviol and stevioside in diabetes induced L6 and 3T3L1 cells | |
| Di Tomo et al. | Centella asiatica and lipoic acid, or a combination thereof, inhibit monocyte adhesion to endothelial cells from umbilical cords of gestational diabetic women | |
| CN105495258A (en) | Fruit beverage facilitating reduction of uric acid | |
| CN110151885A (en) | A kind of niacinamide-containing mononucleotide formula is in the application for preparing anti-aging and nutritive health care product or medicine field | |
| CN109963574A (en) | It include composition of the fat stem cell source efflux body as active constituent for prevent or treat liver fibrosis | |
| CN105943958A (en) | Inonotus obliquus composite solid particles for treating gout and preparing method thereof | |
| CN103550281B (en) | The pharmaceutical composition of a kind of prevention and therapy diabetes and complication thereof and preparation thereof | |
| Suthar et al. | Efficacy and safety of PDM011011 capsules as compared to metformin in subjects with type-2 diabetes mellitus: An open-label, randomized, active-controlled, multicentric, phase III study | |
| CN106619624A (en) | Application of epalrestat in preparation of drugs for treating hyperuricemia and gout | |
| CN104940181B (en) | The purposes of β hydroxybutyric acids or its pharmaceutically acceptable salt | |
| CN109771497A (en) | A kind of blood pressure decreasing capsule and preparation method | |
| CN101411781A (en) | Use of pu'er tea in preparing medicament for treating or preventing diabetes | |
| CN105287755B (en) | A kind of Chinese medicine composition treating sepsis cardiac dysfunction | |
| CN104784475B (en) | A kind of Traditional Chinese medicine formula extract and its application for whitening spot-removing | |
| CN105055399A (en) | Natural product composition for preventing and treating diabetes and application thereof | |
| CN104013851B (en) | A kind of Chinese medicine preparation treating tinea pedis | |
| CN102793870A (en) | Chinese herbal medicine for treating renal calculi | |
| CN104997812A (en) | Drug for resisting cerebral ischemia-reperfusion injury as well as preparation method and application of drug | |
| CN101129431A (en) | Traditional Chinese medicine composition for preventing and controlling cardiovascular disease and relative disease, method of preparing the same and application of the same | |
| CN116585379B (en) | Traditional Chinese medicine composition, method and application for preventing and treating hyperuricemia and gout | |
| WO2013140153A2 (en) | Cosmetic and pharmaceutical uses of saccharides | |
| CN108524850A (en) | A kind of liquor preparation for enhancing immune prevention cardiovascular and cerebrovascular disease | |
| Kamble et al. | Study of serum fucose level in breast malignancy | |
| Wei et al. | [Retracted] Impact of Small Incision Reduction and Suture Linked with Functional Appliance of Sufferers with Irrecoverable TMJ Anterior Disc Displacement | |
| Kumar | A Study of the Effect of Yogic intervention on Blood uric acid Level in Gout Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190823 |